Our lab develops strategies to target immunosuppressive cells, molecules and pathways to re-activate anti-tumor immune responses in cancer patients. Our lead antibody targeting Clever-1 is under clinical development for the treatment of various solid tumors. The research group is led by Adjunct Professor Maija Hollmén.

Read more: https://hollmenlab.com/